Compare Hilton Hotels Corporation Common Stock (HLT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Neurocrine Biosciences Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.19 (market cap $72.14B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HLT | NBIX | |
|---|---|---|
Market Cap | $72.14B | $14.60B |
Volume | 862,817 | 1,075,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $185.50 |
52-Week Low | $256.96 | $123.10 |
Typical Hold Time | 138 Days | 23 Days |
Enterprise Value | $85.15B | $14.61B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $323.29, up 0.21% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $12.04B in 2025, with net income of $1.46B and consistent quarterly EPS beats. Recent news highlights upcoming Q3 2026 earnings and positive travel trends for 2027.
Outlook remains positive with a consensus price target of $348.11, though high debt levels and valuation multiples pose risks. Earnings growth and global expansion in Asia present opportunities, but investors should monitor interest expense and competitive pressures in the hospitality sector.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
